BRITAIN'S National Health
Service may introduce incentives
to take advantage of the budget
savings achievable by biosimilar
substitution, as biosimilars become
more widely approved through
Europe and begin to occupy a larger
proportion of the market.
Speaking at a conference in
London this week Malcolm Qualie,
pharmacy lead, specialised services
at NHS England, gave the example
of Hospira’s infliximap biosimilar
Inflectra, which he said could save
Europe €20 billion by 2020, he said.The above article was sent to subscribers in Pharmacy Daily's issue from 27 Nov 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Nov 15
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.